Provided herein are antibodies that specifically bind to human tissue factor (TF), anti-TF antibody-drug conjugates (ADCs), and compositions comprising the antibodies or ADCs. Also provided herein are methods of making and using the antibodies or ADCs, such as therapeutic and diagnostic methods.

An example method includes the following operations: obtaining a dotting parameter based on a mixture including a test sample and a reagent, where the reagent includes a polycation; using the dotting parameter to identify at least one of a potential presence of a direct oral factor Xa inhibitor in the test sample or an estimated concentration of the direct oral factor Xa inhibitor in the test sample; and reporting a result that is based on the potential presence or the estimated concentration,

A highly sensitive blood coagulation test reagent that enables determining and evaluating bleeding risk of direct oral anticoagulants (DOACs) and the like accurately in hemorrhagic diseases, and the like are provided. A blood coagulation test reagent containing: an active form of a blood coagulation factor XI (FXIa); and tissue factor (TF). A blood coagulation test method including a step of measuring the amount of thrombin generated by reacting a biological sample as a test specimen with a test reagent containing: 0.5 pM to 1,000 pM of an active form of a blood coagulation factor XI(FXIa); and 1 fM to 1,000 fM of tissue factor.

The present invention pertains to the field of coagulation diagnostics and relates to a prothrombin time reagent on the basis of recombinant or native tissue factor protein and phospholipids, which reagent can be stabilized by the addition of an iron chelator from the groups of siderophores and 3,5-diphenyl-1,2,4-triazoles.

A blood coagulation analyzing method according to one or more aspects may include: calculating a coagulation time based on data representing a coagulation curve of a change in an optical detection value of a blood specimen added with a reagent for starting a coagulation reaction; calculating an index value related to derivatives calculated concerning the coagulation curve represented by the data used in the calculating the coagulation time; and determining whether an early reaction error has occurred based on a comparison result obtained by comparing the index value to a predetermined threshold.

Disclosed is an apparatus for testing blood coagulation indicators, including a blood sample receiving and preprocessing unit, and the blood preprocessing part is configured to remove or neutralize the anticoagulation effect of the artificially added anticoagulant in the blood sample; a reacting unit in which the blood undergoes a clotting process; a blood coagulation indicator analyzing and computing unit which may measure an electrical signal passing through the blood sample during the course of testing to obtain measurement results reflecting a time measurement function; and a result displaying unit. Further disclosed is a method for testing coagulation indicators of a blood sample using the apparatus.

The present disclosure provides compositions, kits, and methods relating to the identification and treatment of immunothrombotic conditions. In particular, the present disclosure provides novel compositions and methods for identifying whether a subject suffers from an immunothrombotic condition based levels of expression and activation of Tissue Factor (TF) and other immunothrombotic biomarkers.

What is described is a kit for preparing a liquid thromboplastin reagent for a prothrombin time assay. The kit simplifies and minimizes reagent preparation time and is stable for 2-5 years.

Provided herein are antibodies that specifically bind to human tissue factor (TF), anti-TF antibody-drug conjugates (ADCs), and compositions comprising the antibodies or ADCs. Also provided herein are methods of making and using the antibodies or ADCs, such as therapeutic and diagnostic methods.

Test strips for determining the activity of a coagulation factor in a blood sample are provided. The strip comprises a support, a sample inlet port for deposition of a blood sample, and a reaction area comprising a blood coagulation reagent. The sample inlet port is connected to the reaction area, and the coagulation reagent comprises blood plasma deficient in the coagulation factor for which activity is to be measured, an ionic citrate source an ionic calcium source, and either one or more coagulation contact phase activator reagents and phospholipids or a mixture of tissue factor and phospholipids. The disclosure further relates to in vitro methods for measuring an activity of a coagulation factor.